Evidence map›Paper›PMID 41882271›Full record

ArticleAAPS PharmSciTech2026

Design and Development of Prolong-acting Intelligent Nano-depot (PaIND) for Improving Patient Adherence.

Hardik Rana, Shreya Gohel, Prachi Rabari, Dhruvixa Patel, Vaishali Thakkar, Tejal Gandhi

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hardik RanaDepartment of Pharmaceutics, Anand Pharmacy College, Anand, 388001, Gujarat, India. hardikrana1439@gmail.com.ORCID http://orcid.org/0000-0002-2159-7665
Shreya GohelDepartment of Pharmaceutics, Anand Pharmacy College, Anand, 388001, Gujarat, India.ORCID http://orcid.org/0009-0009-3203-3468
Prachi RabariDepartment of Pharmaceutics, Anand Pharmacy College, Anand, 388001, Gujarat, India.ORCID http://orcid.org/0009-0002-9249-3983
Dhruvixa PatelDepartment of Pharmaceutics, Anand Pharmacy College, Anand, 388001, Gujarat, India.ORCID http://orcid.org/0009-0006-9663-9555
Vaishali ThakkarDepartment of Pharmaceutics, Anand Pharmacy College, Anand, 388001, Gujarat, India.ORCID http://orcid.org/0000-0001-6332-7703
Tejal GandhiDepartment of Pharmaceutics, Anand Pharmacy College, Anand, 388001, Gujarat, India.ORCID http://orcid.org/0000-0002-2011-1555

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medication adherence is a major limitation in the current era. The purpose of the current research was to develop a Prolong-acting intelligent nano-depot (PaIND) for patients diagnosed with hypercholesterolemia, utilizing Rosuvastatin (RSV), to reduce the need for frequent medication administration. PaIND were formulated with poly(lactic-co-glycolic acid 75:25) (PLGA) as the biodegradable polymer, Dimethyl sulfoxide (DMSO) as the solvent, sesame oil as the oil, Span 80 and Tween 80 as the surfactant and co-surfactant, respectively. PaIND was developed systematically by application of quality by design (QbD). A risk assessment approach and Taguchi design were used to screen for significant materials (CMAs) and process attributes (CPPs). PaIND was optimized by applying central composite design (CCD). PaIND was designed and evaluated for prolonged controlled RSV release, gelling time, nano-sized particles, stability, sterility, and other parameters. The chosen excipients showed controlled delivery over a prolonged period, with no signs of burst release. Higher delta values and S/N ratios in the Taguchi design indicate a significant influence of the amount of PLGA, span 80, and tween 80 on the quality of PaIND. Quadratic effect was observed for each CMA on chosen CQAs in CCD. The optimum PaIND showed 86.99% RSV release in 30 days, a 173 nm size, and a 3.6 s gelling time-physical properties aligned with prolonged drug release. Lower PDI and viscosity, negative zeta potential, high transmittance and entrapment efficiency, improved stability and sterility, better use of PaIND. PaIND was successfully designed and developed, integrating recent regulatory compliance requirements. The newer system is highly patient-friendly and ready for commercial use following successful preclinical trials.

Indexed as

Delayed-Action PreparationsNanoparticlesChemistry, PharmaceuticalDimethyl SulfoxideDrug CarriersDrug Delivery SystemsDrug LiberationExcipientsHexosesHumansMedication AdherenceParticle SizePolylactic Acid-Polyglycolic Acid CopolymerPolymersPolysorbatesRosuvastatin CalciumDelayed-Action PreparationsDimethyl SulfoxideDrug CarriersExcipientsHexosesPolylactic Acid-Polyglycolic Acid CopolymerPolymersPolysorbatesRosuvastatin CalciumSolventssorbitan monooleateSurface-Active AgentsCCDchronic diseasepatient-friendlyprolong-acting formulationtaguchi design

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.